Main public logs

Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

• 02:13, 10 April 2025 Parth Vikram Singh talk contribs uploaded a new version of File:T1.png
• 02:12, 10 April 2025 Parth Vikram Singh talk contribs created page File:T1.png
• 02:12, 10 April 2025 Parth Vikram Singh talk contribs uploaded File:T1.png
• 02:03, 10 April 2025 Parth Vikram Singh talk contribs created page File:Lpkg.png
• 02:03, 10 April 2025 Parth Vikram Singh talk contribs uploaded File:Lpkg.png
• 01:59, 10 April 2025 Parth Vikram Singh talk contribs created page File:Leavactable1.png
• 01:59, 10 April 2025 Parth Vikram Singh talk contribs uploaded File:Leavactable1.png
• 01:50, 10 April 2025 Parth Vikram Singh talk contribs created page File:LevT1.png
• 01:50, 10 April 2025 Parth Vikram Singh talk contribs uploaded File:LevT1.png
• 17:54, 9 April 2025 Parth Vikram Singh talk contribs created page File:Levaf3.png
• 17:54, 9 April 2025 Parth Vikram Singh talk contribs uploaded File:Levaf3.png
• 17:11, 9 April 2025 Parth Vikram Singh talk contribs created page File:Levaf2.png
• 17:11, 9 April 2025 Parth Vikram Singh talk contribs uploaded File:Levaf2.png
• 16:59, 9 April 2025 Parth Vikram Singh talk contribs created page File:Levact3.png
• 16:59, 9 April 2025 Parth Vikram Singh talk contribs uploaded File:Levact3.png
• 16:51, 9 April 2025 Parth Vikram Singh talk contribs uploaded a new version of File:Levat1.png
• 11:27, 9 April 2025 Parth Vikram Singh talk contribs uploaded a new version of File:Levf1.png
• 11:15, 9 April 2025 Parth Vikram Singh talk contribs created page File:Levf1.png
• 11:15, 9 April 2025 Parth Vikram Singh talk contribs uploaded File:Levf1.png
• 10:26, 9 April 2025 Parth Vikram Singh talk contribs created page File:Levat2.png
• 10:26, 9 April 2025 Parth Vikram Singh talk contribs uploaded File:Levat2.png
• 09:06, 9 April 2025 Parth Vikram Singh talk contribs uploaded a new version of File:Levat1.png
• 08:51, 9 April 2025 Parth Vikram Singh talk contribs created page File:Levat1.png
• 08:51, 9 April 2025 Parth Vikram Singh talk contribs uploaded File:Levat1.png
• 09:56, 8 April 2025 Parth Vikram Singh talk contribs created page Levacetylleucine (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=levacetylleucine |indicationType=treatment |indication=AQNEURSA is FDA approved for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥5% and greater than placebo) are abdominal pain, dysphagia, upper respiratory tract infections, and vomiting. |...")
• 05:12, 8 April 2025 Parth Vikram Singh talk contribs created page File:Xolt2.png
• 05:12, 8 April 2025 Parth Vikram Singh talk contribs uploaded File:Xolt2.png
• 04:58, 8 April 2025 Parth Vikram Singh talk contribs created page File:Xol2.png
• 04:58, 8 April 2025 Parth Vikram Singh talk contribs uploaded File:Xol2.png
• 04:33, 8 April 2025 Parth Vikram Singh talk contribs created page File:Xol str.png
• 04:33, 8 April 2025 Parth Vikram Singh talk contribs uploaded File:Xol str.png
• 15:20, 7 April 2025 Parth Vikram Singh talk contribs created page Mavorixafor (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Mavorixafor in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported U...")
• 10:10, 7 April 2025 Parth Vikram Singh talk contribs created page Imetelstat (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Imetelstat in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Us...")
• 03:47, 7 April 2025 Parth Vikram Singh talk contribs created page User:Parth Vikram Singh (Created page with "{| class="wikitable" |- ! sfgh ! fgh ! ! ! ! fgh ! fgxh |- | fsgh | | | | | | fgxh |- | | | | | | | |- | | | | | | | |- | | | | | | | |- | | | | | | | |- | | | | | | | |- | | | | | | | |}")
• 03:40, 7 April 2025 Parth Vikram Singh talk contribs created page Berdazimer (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |indication=abc |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Berdazimer in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use''...")
• 17:06, 6 April 2025 Parth Vikram Singh talk contribs created page Template:PVS (Created page with "Parth Vikram Singh, MBBS[mailto:dr.parthvikramsingh@gmail.com]")
• 10:33, 6 April 2025 Parth Vikram Singh talk contribs created page Elafibranor (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Elafibranor in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-...")
• 09:18, 6 April 2025 Parth Vikram Singh talk contribs created page SOFDRA (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=sofpironium |aOrAn=an |indicationType=treatment |indication=SOFDRA is an anticholinergic FDA approved for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. |adverseReactions=• Most common adverse reactions (incidence ≥2%) are:  dry mouth,  vision blurred,  application site pain,  application site erythema,  mydriasis...")
• 07:15, 6 April 2025 Parth Vikram Singh talk contribs created page Sofpironium (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=sofpironium |aOrAn=an |indicationType=treatment |indication=SOFDRA is an anticholinergic approved for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is li...")
• 10:23, 5 April 2025 Parth Vikram Singh talk contribs created page Ensifentrine (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=ensifentrine |aOrAn=a |indicationType=treatment |indication=OHTUVAYRE is a phosphodiesterase 3 (PDE3) inhibitor and phosphodiesterase 4 (PDE4) inhibitor approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'...")
• 17:13, 3 April 2025 Parth Vikram Singh talk contribs created page Vorasidenib (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Vorasidenib in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-...")
• 17:20, 2 April 2025 Parth Vikram Singh talk contribs created page Palopegteriparatide (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Palopegteriparatide in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Gu...")
• 11:28, 1 April 2025 Parth Vikram Singh talk contribs created page Seladelpar (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Seladelpar in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Seladelpar i...")
• 03:37, 31 March 2025 Parth Vikram Singh talk contribs created page Lazertinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Lazertinib |aOrAn=a |indicationType=treatment |indication=LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. |adverseReactions=The following...")
• 16:00, 30 March 2025 Parth Vikram Singh talk contribs created page Landiolol (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Landiolol in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Su...")
• 11:10, 30 March 2025 Parth Vikram Singh talk contribs created page Acoramidis (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=acoramidis |aOrAn=a |drugClass=transthyretin stabilizer |indicationType=treatment |indication=ATTRUBY is a transthyretin stabilizer that is FDA approved for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. |adverseReactions=• There was a higher frequency of gas...")
• 13:12, 28 March 2025 Parth Vikram Singh talk contribs created page Revuforj (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Revumenib |aOrAn=a |drugClass=Menin inhibitor |indicationType=treatment |indication=Revumenib is a menin inhibitor that is FDA approved for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. |hasBlackBoxWarning=Yes |adverseReactions=Common adverse reactions include hemorrhage, nausea, ph...")
• 02:46, 28 March 2025 Parth Vikram Singh talk contribs created page Crinecerfont (Created page with "{{DrugProjectFormSinglePage |OTC=Yes |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Crinecerfont in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of C...")
• 13:52, 27 March 2025 Parth Vikram Singh talk contribs created page Revumenib (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Revumenib |aOrAn=a |drugClass=Menin inhibitor |indicationType=treatment |indication=Revumenib is a menin inhibitor that is FDA approved for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. |hasBlackBoxWarning=Yes |adverseReactions=Common adverse reactions include Bleedin...")
• 02:47, 13 February 2025 Parth Vikram Singh talk contribs created page Inavolisib (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Inavolisib |aOrAn=a |drugClass=phosphoinositide 3-kinase inhibitors |indicationType=treatment |indication=Inavolisib is a phosphoinositide 3-kinase inhibitor that is FDA approved for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer Breast cancer,...")